Advancing Interdisciplinary Care in Prostate Cancer Clinical Updates for Urology and Oncology Healthcare Professionals

Advancing Interdisciplinary Care in Prostate Cancer: Clinical Updates for Urology and Oncology Healthcare Professionals

Advancing Interdisciplinary Care in Prostate Cancer: Clinical Updates for Urology and Oncology Healthcare Professionals
Dr. Sartor reviews available therapies, guidelines, and considerations for treatment of prostate cancer.

Available credits: 0.50

Time to complete: 30 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Prostate cancer is the third leading cause of cancer death in men in the United States, accounting for 8% of all cancer deaths with an estimated 26,730 deaths in 2017. The recent development of novel hormonal agents, chemotherapy, and immunotherapy has dramatically changed the treatment paradigm of metastatic castration-resistant prostate cancer (mCRPC). Until 2010, docetaxel was the only agent approved by the US Food and Drug Administration (FDA) to treat mCRPC. Sipuleucel-T and cabazitaxel were both FDA approved in 2010, followed by abiraterone acetate in 2011, enzalutamide in 2012, and most recently, radium-223 dichloride in 2013. With the approval of several new agents by the FDA in recent years, there are now multiple treatment options for patients with mCRPC, making clinical decision-making more difficult. There are also guideline recommendations published from the NCCN, American Urological Association (AUA), and American Society of Clinical Oncology (ASCO), which can contribute to variations in treatment approaches.

    Additionally, treatment in an outpatient, office-based setting may result in cost savings compared to both hospital inpatient and outpatient settings. Other advantages include safe and easy drug administration, avoidance of hospitalization, familiarity with a particular facility, enhanced physical comfort, and improved psychological well being.

    This activity will review available therapies for mCRPC, selecting and sequencing individualized therapy, treatment guidelines, and considerations for treatment.

  • Learning Objectives

    • Analyze efficacy and safety data of currently available therapy for the treatment of mCRPC to select and sequence therapy
    • Develop individualized treatment strategies consistent with current guidelines for patients with mCRPC based on patient- and disease-related characteristics
  • Target Audience

    This activity is intended for genitourinary oncologists, medical oncologists, urologists, radiation oncologists, oncology and urology nurses, fellows, and pharmacists.

  • Disclosure of Conflicts of Interest

    AXIS Medical Education requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by AXIS for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
    AXIS will identify, review, and resolve all conflicts of interest that faculty, authors, activity directors, planners, managers, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.

    The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity: A Oliver Sartor, MD, reported a financial interest/relationship or affiliation in the form of: Consultant, AstraZeneca, Bayer, Bellicum, Bristol-Myers Squibb, Celgene, Dendreon, EMD Serono, Johnson & Johnson, Medivation, Oncogenex, sanofi-aventis, Tokai; Grant/Research support: Bayer, Endocyte, Innocrin, Johnson & Johnson, sanofi-aventis.

    The planners and managers reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

    The following AXIS planners and managers, Linda Gracie-King, MS, Jocelyn Timko, and Marilyn Haas, PhD, RN, CNS, ANP-BC hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest of any amount during the past 12 months. Stephanie Sutphin, PharmD, reports a financial interest/relationship or affiliation in the form of Advisory board: Seattle Genetics and Amgen Biosimilars.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Credit Designation for Physicians
    AXIS Medical Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™.

    Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Credit Designation for Pharmacists
    This knowledge-based activity is approved for 0.50 contact hours of continuing pharmacy education credit UAN JA4008106-0000-18-004-H01-P.

    Credit Designation for Nursing
    AXIS Medical Education designates this continuing nursing education activity for 0.50 contact hours.

    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.

    AXIS Contact Information:
    For information about the certification of this activity, please contact AXIS at

  • Commercial Support

    This activity is supported by an educational grant from Sanofi Genzyme.

  • Terms of Use

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational ("off-label") uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

    Method of Participation and Request for Credit:
    To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately. For pharmacists, your record will be uploaded to CPE Monitor.

    There is no fee for this educational activity.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

Sign-up for the Global Women's Health Academy newsletters.
Comprehensive Women's Health Education.

Better education for a better you.

* Required

Join the Global Women's Health Academy of learners.
Registration is free and easy.

Register Now